Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Hansa Biopharma AB (publ)
  6. News
  7. Summary
    HNSA   SE0002148817


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hansa Biopharma interim report Jan-Sep 2020

10/22/2020 | 02:01am EDT

Hansa Biopharma advances to commercial stage following conditional EU approval of Idefirix; Positive high-level data from investigator-initiated phase 2 trial with imlifidase in anti-GBM

Lund October 22, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January - September, 2020.

Highlights for the third quarter 2020

· The EU Commission granted conditional approval for Idefirix® (imlifidase) in highly sensitized kidney transplant patients in the European Union. Idefirix is the Company's first approved drug and will transform Hansa Biopharma into a commercial stage biopharmaceutical company.
· Entered exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in select indications. The agreement with Sarepta includes an upfront payment and will potentially generate milestone payments to Hansa totaling up to USD 397.5m plus royalties on imlifidase enabled gene therapy sales. All imlifidase sales will be booked by Hansa. 
· Anti-GBM: Reported positive high-level data from investigator-initiated phase 2 trial with imlifidase to treat anti-GBM disease with two-thirds of patients achieving dialysis independence six months after treatment. The positive data marks an important milestone for the Company's expansion of imlifidase outside transplantation.
· US trial in kidney transplantation: Recruitment of first patient expected in H1 2021, given the continued impact of the COVID-19 pandemic in the US and the timeline to finalize the study protocol. Potential BLA submission is expected by 2023 under the accelerated approval path. 
· Pipeline: Enrollment in both phase 2 studies in GBS and AMR have been temporarily halted for the past months due to the COVID-19 pandemic. Reinitiation of enrollment expected in Q4 2020 under a risk-based site-by-site approach. Completion of enrollment in both studies is expected in the second half of 2021.
· Hansa Biopharma AB  certified as a Great Place to Work®  following the results of a company-wide employee survey and a review of policies.
· SEK 1.1bn (USD 121m) raised in a directed share issue of 4.4 million ordinary shares. The share issue was multiple times oversubscribed due to high demand from US, European and Swedish institutional investors. The capital raised will help finance the Company's R&D pipeline as well as fund the launch and commercialization of imlifidase in kidney transplantation.
· Max Sakajja, VP Corporate Development, appointed to a new role as VP International Markets to prepare Hansa Biopharma's expansion strategy outside the EU. The role reports into the CCO and is part of Hansa's broader leadership team.
· Investments in R&D and SG&A increased in the third quarter to SEK 71m (Q3'19: SEK 47m) and SEK 52m (Q3'19: SEK 46m), respectively. Cash position was SEK 1,476m at the end of September 2020. Cash flow from operating activities for the third quarter ended at SEK 5m (Q3'19: SEK -80m).

Søren Tulstrup, President and CEO of Hansa Biopharma, comments
"Hansa Biopharma's evolution into a fully integrated biopharmaceutical company took a major step forward in the third quarter following the conditional approval of Idefirix (imlifidase) by the European Commission for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.

The European approval serves as a validation of the potential of our proprietary drug development platform and will transistion Hansa Biopharma into the next phase as a commercial stage biopharmaceutical company.

We are also excited about the progress of our efforts beyond transplantation. In July we announced the achievement of another landmark milestone with the exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as a potential pre-treatment prior to the administration of gene therapy. The agreement with Sarepta is exclusive for the use in Duchenne and and Limb-Girdle indications and serves as a validation of our enzyme technology as we expand beyond transplantation.

Late Septermber we also announced positive high-level data from the investigator-initiated phase 2 trial with imlifidase to treat anti-GBM disease. Data from the trial shows that imlifidase leads to rapid clearance of anti-GBM antibodies, with two-thirds of patients achieving dialysis independence six months after treatment. We are very encouraged by the positive outcome as anti-GBM is the first IgG-mediated disease outside transplantation, where imlifidase has been shown to stop an immunologic attack. 

Our strong progress across our platform of immunomodulatory enzymes has also been recognized by our investors, as our investor base has continued to expand in Sweden and internationally. End of September, the number of shareholders has increased to more than 18,000 investors, with 45% of the shares now owned by international investors and institutions. We see this as a testimony to our recent progress and a strong and growing international interest in Hansa Biopharma. 

While an exciting and transformative year has impacted us in a postive way, we are still seeing negative effects due to the widespread impact from the COVID-19 pandemic. Enrollment in the phase 2 studies in GBS and AMR has been temporarily halted for the past months, and we expect to reinitiate enrollment of these studies in the fourth quarter 2020 under a risk-based, site-by-site approach. 

In the US, the proposed study protocol for a randomised controlled trial (RCT) targeting highly-sensitized kidney patients was submitted to the FDA in June, 2020. Discussions are currently ongoing with the FDA and, once the final protocol has been agreed upon, we will proceed to set up centers in the US and start to enroll patients. Given the continued impact of the COVID-19 pandemic and the timeline for finalization of the study protocol, we expect recruitment of the first patient to be in the first half of 2021 with a potential BLA submission in 2023. 

Lastly, I also want to highlight that Hansa Biopharma AB recently got certified as a Great Place to Work®. This certification reflects our efforts to build a strong organization through attracting, developing and retaining the very best talent in the industry as we continue our growth trajectory and development into a fully integrated biopharmaceutical company.

I look forward to keeping you updated on the progress of our journey." 

Upcoming milestones and news flow
Q4 2020     Kidney transplantation EU: Commercial launch 
H1 2021     Kidney transplantation US: First patient dosed / RCT
H1 2021     NiceR: Completion of GMP process; initiate IND-enabling tox studies 
H2 2021     AMR Phase 2 study: Complete enrollment 
H2 2021     GBS Phase 2 study: Complete enrollment 
2022           Kidney transplantation US: Complete enrollment / RCT
H2 2022     AMR Phase 2 study: Data read out 
H2 2022     GBS Phase 2 study: Data read out 
2023           Kidney transplantation US: 12 months follow-up on eGFR completed / RCT
2023           Kidney transplantation US: BLA submission

Capital Markets Day
Hansa Biopharma to host Capital Markets Day on Thursday October 29, 2020 in Copenhagen 

The CMD event will be focused around Hansa Biopharma's transformation into a fully integrated and commercial stage biopharmaceutical company and will highlight the potential of the Company's unique antibody-cleaving enzyme platform beyond transplantation in areas such as autoimmunity and gene therapy. 

The event will feature both senior management and external guest speakers. The event will be livestreamed and available for all viewers on our web at http://www.hansabiopharma.com. 

If you wish to participate in the CMD virtually, kindly sign up using the following link https://hansa.eventcdn.net/2020cmd/

No conference call scheduled on Oct 22, 2020 
Since Hansa Biopharma will host its Capital Markets Day a week later than the Q3'2020 report it has been decided to incoporate relevant elements and updates from the third quarter into the CMD program and presentations rather than hosting a seperate Q3 conference call. There will be opportunites to ask questions during the Capital Markets Day.

The interim report and latest investor presentation can be downloaded from our web 
Interim report January - September 2020 

Investor road show presentation Q3, 2020 

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com 

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, gene therapy and cancer. The Company's lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020. Hansa's research and development program is advancing the Company's enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases, gene therapy and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.



(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
HANSA BIOPHARMA AB (PUBL) -2.59% 150.25 Delayed Quote.-35.84%
HANSAE YES24 HOLDINGS CO., LTD -1.33% 9660 End-of-day quote.26.11%
SAREPTA THERAPEUTICS, INC. -1.98% 78.38 Delayed Quote.-53.02%
05/12HANSA BIOPHARMA  : Bulletin from the Annual General Meeting in Hansa Biopharma A..
04/22HANSA BIOPHARMA  : interim report Jan-Mar 2021
04/14HANSA BIOPHARMA  : to host conference call to provide interim results from Q1 20..
04/09HANSA BIOPHARMA : Notice to Annual General Meeting
04/08HANSA BIOPHARMA  : publishes Annual Report 2020
03/30HANSA BIOPHARMA  : Argenx Partner To Assess Potential Of Combining Two IgG-Modul..
03/29HANSA BIOPHARMA  : enters preclinical research collaboration with argenx
03/01HANSA BIOPHARMA  : appoints Dr. Magnus Korsgren as Head of Research & Developmen..
02/04HANSA BIOPHARMA  : year-end report Jan-Dec 2020
01/27HANSA BIOPHARMA  : to host conference call to provide Year-End report 2020 and B..
More news
Sales 2021 86,5 M 10,0 M 10,0 M
Net income 2021 -465 M -54,0 M -54,0 M
Net cash 2021 884 M 102 M 102 M
P/E ratio 2021 -14,9x
Yield 2021 -
Capitalization 6 860 M 794 M 796 M
EV / Sales 2021 69,1x
EV / Sales 2022 35,8x
Nbr of Employees 101
Free-Float 95,9%
Duration : Period :
Hansa Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANSA BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 5
Average target price 316,60 SEK
Last Close Price 154,25 SEK
Spread / Highest target 166%
Spread / Average Target 105%
Spread / Lowest Target 23,2%
EPS Revisions
Managers and Directors
Søren Tulstrup President & Chief Executive Officer
Donato Spota Chief Financial Officer & Senior Vice President
Ulf Arne Wiinberg Chairman
Christian Kjellman Chief Operating & Scientific Officer
Achim Kaufhold Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.93.81%81 297
LONZA GROUP AG15.68%53 313
CELLTRION, INC.-24.79%32 426
SEAGEN INC.-12.42%27 835